A Multi-center Prospective Randomized Controlled Study on Clinical and Radiographic Analysis of ProDisc-C Vivo

Sponsor
Peking University People's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03367039
Collaborator
(none)
648
2
84

Study Details

Study Description

Brief Summary

The object of this study is to assess the long-term safety and efficacy of cervical disc replacement with the ProDisc-C vivo Cervical Disc in a prospective, randomized, multi-center trial with 7 years of follow-up.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ProDisc-C vivo
  • Procedure: Anterior cervical discectomy fusion
N/A

Detailed Description

This is a prospective, randomized, multicenter trial at 7 years of follow-up comparing ProDisc-C vivo artificial cervical disc replacement and ACDF (Anterior cervical discectomy fusion) to treat degenerative disc disease (DDD). 648 DDD patients (age from 20 to 70) from several hospitals matching the inclusion criteria will be randomly assigned to two groups (324 patients in each group). One group will be treated with ProDisc-C vivo disc replacement. The other group will be treated with ACDF. The clinical outcomes and radiographic measurements will be compared between two groups at 1.5, 3, 6, 12, 24, 36, 60, and 84 months after the surgical treatments.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
648 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
648 DDD patients (age from 20 to 70) from several hospitals matching the inclusion criteria will be randomly assigned to two groups (324 patients in each group). One group will be treated with ProDisc-C vivo disc replacement. The other groups will be treated with ACDF.648 DDD patients (age from 20 to 70) from several hospitals matching the inclusion criteria will be randomly assigned to two groups (324 patients in each group). One group will be treated with ProDisc-C vivo disc replacement. The other groups will be treated with ACDF.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical and Radiographic Analysis of ProDisc-C Vivo to Treat Degenerative Disc Disease: A 7-year Follow-up, Multi-center, Prospective, Randomized, Controlled Clinical Trial.
Anticipated Study Start Date :
Mar 1, 2018
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: ProDisc-C vivo

This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).

Procedure: ProDisc-C vivo
Total Disc Replacement using ProDisc-C vivo.

Active Comparator: Anterior cervical discectomy fusion

This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).

Procedure: Anterior cervical discectomy fusion
Anterior Cervical Discectomy and Fusion

Outcome Measures

Primary Outcome Measures

  1. Change of overall success rate [The overall success will be assessed at each time point (1.5, 3, 6, 12, 24, 36, 60, and 84 months after the surgical treatments).]

    A patient's outcome was considered an overall success if all of the following conditions were met: 1) postoperative (Neck Disability Index) NDI score improvement of at least a 15-point increase from preoperative score; 2) maintenance or improvement in neurological status; 3) disc height success; 4) no serious adverse event classified as implant associated or implant/surgical procedure associated; and 5) no additional surgical procedure classified as a "failure".

Secondary Outcome Measures

  1. Change of sagittal angular motion [The radiographic outcomes will be obtained at each study point (before surgery,1.5, 3, 6, 12, 24, 36, 60, and 84 months after the surgical treatments).]

    Neutral anteroposterior and lateral radiographs and dynamic flexion-extension lateral radiographs will be measured.

  2. Change of neck disability index scores [The NDI scores will be obtained at each study point (before surgery,1.5, 3, 6, 12, 24, 36, 60, and 84 months after the surgical treatments).]

    The neck disability index(NDI) questionnaire measures the level of pain and disability associated with various activities. The NDI is a 10-item, 50-point index that assesses different aspects of daily functioning in patients with neck pain. Each item is scored 0 to 5. The NDI score is a sum of the scores of the10-item. Clinical effects will be evaluated based on scores of the NDI. Higher values represent a better outcome.

  3. Change of Arm and Neck pain intensity [Neck and arm pain scores will be measured at each study point (before surgery,1.5, 3, 6, 12, 24, 36, 60, and 84 months after the surgical treatments).]

    Neck and arm pain scores will be measured using a visual analogue scale (VAS) from "0' (no sensation) to '100"(the most intense pain imaginable) where 30 means "pain threshold".

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Single-level cervical disc disease.

  • At least one additional confirmatory neuroradiographic study, such as MRI or CT- enhanced myelography that showed findings consistent with clinical findings and complaints.

Exclusion Criteria:
  • Patients have cervical spinal conditions other than single-level symptomatic degenerative disc disease or evidence of instability.

  • Symptomatic disc disease at level C2 -3 or C7-T1.

  • A history of discitis.

  • A medical condition that required medication,such as steroids or nonsteroidal antiinflammatory medications that could interfere with fusion.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking University People's Hospital

Investigators

  • Principal Investigator: Zhenqi Zhu, Master, Peking University People's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zhu Zhenqi, Principal Investigator, Peking University People's Hospital
ClinicalTrials.gov Identifier:
NCT03367039
Other Study ID Numbers:
  • Prodisc-C vivo
First Posted:
Dec 8, 2017
Last Update Posted:
Dec 8, 2017
Last Verified:
Dec 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Zhu Zhenqi, Principal Investigator, Peking University People's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2017